T cells for advanced synovial sarcoma or myxoid round cell liposarcoma
Mené sur 52 patients HLA-A*02+ atteints d'un sarcome synovial ou d'un liposarcome myxoïde à cellules rondes non résécable ou de stade métastatique et exprimant MAGE-A4 (durée médiane de suivi : 32,6 mois), cet essai international de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité de l'afamitresgène autoleucel (une thérapie adoptive par lymphocytes T) après l'échec de plusieurs lignes thérapeutiques
Transgenic T-cell receptor-based immunotherapies hold the potential to revolutionise the treatment of cancer-testis antigen (CTA)-positive cancers. CTAs are exclusively found in immunologically privileged physiological, non-vitally essential adult testicular germ cells and can be massively overexpressed in cancers. 1 One prominently used target for transgenic T-cell receptor-based immunotherapies is intracellular MAGE-A4, which is present in various solid cancers, including synovial sarcoma and myxoid round cell liposarcoma. Notably absent in healthy tissues, or present at inconsequential levels, CTAs are a panec